{
    "2018-08-13": [
        [
            {
                "time": "2018-07-15",
                "original_text": "Novo Nordisk’s Long-Acting Insulins: A Performance Overview",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "long-acting insulins",
                        "performance"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-16",
                "original_text": "Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?",
                "features": {
                    "keywords": [
                        "Victoza",
                        "revenue growth",
                        "Novo Nordisk"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-17",
                "original_text": "Novo Nordisk: A Financial Overview after the First Half of 2018",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "financial overview",
                        "first half 2018"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Novo Nordisk",
                        "J&J",
                        "Allergan",
                        "Editas",
                        "AstraZeneca",
                        "Merck",
                        "Bristol-Myers"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}